Astellas Pharma Inc. has entered an agreement to acquire Ganymed Pharmaceuticals, a German biopharma company focused on the development of antibodies against cancer, for €422 million. Ganymed’s shareholders are also eligible to receive as much as €860 million in payments based on IMAB362 development milestones. Ganymed will become a wholly owned subsidiary of Astellas. The closing, subject to customary regulatory approvals, is expected to be finalized in the coming weeks.   Ganymed has s...